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Pathophysiology and Involvement 
of the Cardiovascular System
David C. Gaze
Abstract
Since the emergence in China of coronavirus disease (COVID-19) in December 
2019; the virus causing the pandemic has infected the human population in almost 
every country and territory on the globe. At the time of writing there are over 84 
million confirmed cases of infection and over 1.8 million deaths globally. Rates of 
infection differ as does the number of severe cases and subsequent deaths between 
countries and continents. This is due in part to lockdown measures, social distanc-
ing and wearing of face coverings. It is also reflected by how healthcare systems 
record coronavirus deaths along with access to testing as well as tracking and 
tracing of infected individuals. Symptoms of COVID-19 include a novel persistent 
cough, fever and anosmia (loss of smell). In most cases, such symptoms are mild. 
A small proportion of those who become infected however, have a severe reac-
tion to the disease affecting multiple organ systems and often require respiratory 
support in the intensive care setting. One such physiological system affected is the 
cardiovascular system. This is likely due to the increased number of ACE2 receptors 
in co-morbid cardiac pathologies. ACE2 receptors serve as the entry port for the 
coronavirus into human cells. Those individuals with underlying cardiovascular risk 
factors are therefore disproportionately at risk of COVID-19 infection. This chapter 
reviews the aetiology and epidemiology of the coronavirus infection; potential 
pathophysiological mechanisms of disease involving the cardiovascular system 
including the clinical utility of biomarkers, electrocardiography and echocardiogra-
phy as well as autopsy cardiac pathology and histopathology.
Keywords: coronavirus disease, cardiovascular system, ACE2 receptors, 
pathophysiological mechanisms
1. Introduction
Coronavirus disease (COVID-19) is an emerging viral disease affecting humans. 
In December 2019, a small series of cases of a pneumonia-like illness presented to a 
hospital in Wuhan, Hubei province in China. The patients displayed bilateral pulmo-
nary infiltrative lesions on chest x-ray. The disease was initially named ‘viral pneumo-
nia of unknown cause’. Many of those presenting with similar symptoms had visited 
or been closely associated with a local wholesale seafood market which also sold 
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exotic species such as civets, snakes, rats and bats. The Chinese Centre for Disease 
Control and Prevention (China CDC) identified the virus as a novel coronavirus 
(nCoV) on 7th January 2020 and renamed the disease ‘pneumonia caused by a novel 
coronavirus. Subsequently on 30th January 2020, the World Health Organisation 
(WHO) referred to the disease as 2019-nCoV. The Coronaviridae study group of the 
International Committee on Taxonomy of Viruses (ICTV) officially named the virus 
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) on 11th February 
2020. The WHO also announced a name change to COronaVIrus Disease 2019 
(COVID-19). The change reflected the greater reporting of a wide range of clinical 
presentations and multiple organ system involvement in severe cases of the disease. 
At the same time, it became apparent the disease was spreading significantly in Hubei 
Province due to an increase in numbers of cases with no identifiable association to the 
seafood market, demonstrating community (person-to-person) transmission.
The rate of escalation of COVID-19 infection is alarming. This is detailed in the 
following statistics (provided by many resources online via China CDC, news out-
lets and social media coverage). A retrospective epidemiological analysis by China 
CDC indicated there were 104 symptomatic cases by 31st December 2019. All cases 
were contained in Hubei province. Between 1st and 10th January 2020, this had 
risen to 566 cases showing symptoms in Hubei, with a further 87 cases in 19 other 
provinces. On January 20th 2020, 5 cases were reported in Beijing and 2 in Shanghai. 
Further analysis demonstrates that the number of cases of COVID-19 present in 
Figure 1. 
Global epidemiology of COVID-19. (a) Confirmed cases of coronavirus and (b) deaths from coronavirus. 
(source WHO live situation dashboard www.covid19.who.int).
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China by 31st January 2020 reached as staggering 32,642. 75% of these were in 
Hubei province. The incidence of the disease in mainland China had escalated to 
over 74,000 cases by 19th February 2020 along with 65 cases and 5 deaths in Hong 
Kong, 10 confirmed cases in Macao and 24 cases and one death in Taiwan.
From mid to late January countries other than China began reporting COVID-
19 cases. The first non-mainland case was a Chinese national from Wuhan who 
travelled to Thailand and tested positive for COVID-19 on the 13th January 2020. 
The first reported case outside of Asia was announced on the 21st January 2020 in 
the United States of America (USA). At the end of February, the WHO declared the 
epidemic as a ‘Public Health Emergency of International Concern’ with evidence of 
infected cases in South Korea (2,337), Japan (210), Italy (650), Iran (245), Singapore 
(96) and USA (59). The cases in Japan are of note as they are associated with a con-
tained infection on the Diamond Princess cruise ship. The ship departed Japan on 
20th January 2020. Five days later a passenger developed a fever and tested positive 
on 1st February 2020 in Hong Kong. The ship returned to Japan and was placed in 
quarantine. By 12th February 492 passengers were tested of which 174 were positive 
for COVID-19. By 19th February 2020, the number of passengers infected rose to 
621 and 705 nine days later. On 11th March 2020, at the daily briefing by the direc-
tor general, Dr. Tedros Adhanom Ghebreyesus, the WHO declared COVID-19 as an 
offically recognised pandemic [1].
It is now a year since the initial outbreak in China. In this short time the WHO 
report via their live situation dashboard [2] to date (5th January 2021) 84,233,579 
confirmed cases globally of which 1,843,293 individuals have died (Figure 1). What 
is shocking and apparent is the upward escalation of these figures on a daily basis, 
especially in the winter months in the Northern Hemisphere.
2. Novel SARS-CoV-2 variants
Late in 2020, two variants of the SARS-CoV-2 virus have been identified. The 
first was identified in September and sequenced in the United Kingdom [3]. The 
‘UK Kent variant’ as it is commonly known has spread rapidly both in the UK and 
internationally. Since 26th December 2020, cases of the new UK Kent Variant 
have also been reported in other EU/EEA countries (Belgium, Denmark, Finland, 
France, Germany, Iceland, Ireland, Italy, the Netherlands, Norway, Portugal, Spain 
and Sweden) and globally (Australia, Canada, Hong Kong SAR, India, Israel, 
Japan, Jordan, Lebanon, South Korea, Switzerland, Singapore). The second variant 
originated in South Africa and is due to the mutation E484K; known as 501.V2. This 
variant was first detected in October 2020 and is associated with over 300 cases as 
of 26th December 2020. Both variants are highly transmissible, but data suggest 
they do not increase the severity of COVID-19 infection [4].
The first variant was identified following a surge in positive cases in the County 
of Kent in South East England and has spread extensively into London and beyond 
(Figure 2). The variant was named as variant under investigation (VUI) followed 
by year, month and number; thus, the designation given was VUI-202012/01 which 
was changed to variant of concern (VOC-202012/01). The variant is defined by 23 
novel mutations. 13 of which are non-synonymous, 4 deletion and 6 synonymous. 
Of concern is nucleotide A23063T in the spike protein representing mutation 
N501Y. This mutation is located in the receptor-binding domain and is associated 
with increased binding affinity to ACE2; making viral entry into host cells easier 
than with the original strain, thus increasing transmissibility. Although more 
transmissible, recent data suggest this variant is less likely to cause severe infection 
and is likely to respond to the current vaccination programme [5].
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3. Coronaviruses
3.1 Taxonomy and morphology
Coronaviruses are a large family of viruses found in animals such as camels, 
dogs, rats, cattle, mice, rats and bats; as well as several viruses known to infect 
humans. They were first discovered in 1968 and named Coronaviridae in 1975 by the 
ITCV. The viruses are positive-sense single stranded RNA viruses with 26 to 32 kb 
genomes and are classified into Alpha, Beta, Gamma and Delta genera (Figure 3). 
The viruses that infect mammals are Alpha and Betacoronaviruses. In humans, 
pathogenic coronaviruses include SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-
HKU1, HCoV-229E, HCoV-NL63 HCoV-OC43. Most are inconspicuous and develop 
into common colds and mild-flu like symptoms, but recently since the emergence of 
SARS and MERS and now SARS-CoV-2, an increasing number of severe illnesses are 
developing associated with novel coronaviruses in humans.
Morphologically, the viral particle of coronaviruses are encased in a bilipid layer 
with three glycoproteins on the surface designated as membrane (M protein), enve-
lope (E protein) and spike (S protein) proteins (Figure 4a). These give the virus the 
characteristic protrusions on the surface akin to a medieval European crown or ‘corona’ 
hence the name coronavirus. An electron micrograph of viral particles isolated in 
alveolar tissue from the first infected case in the United States is shown in Figure 4b.
Utilising cryptoelecton tomography (Cryo-ET), Yao and colleagues determined 
the detailed molecular structure of the novel SARS-CoV-2 enveloped virus and 
elucidated the mechanism of packing the ~30 kb long single RNA into the 80 nm 
diameter luminal space [7].
Figure 2. 
Distribution of confirmed sequenced cases of VOC202012/01 as of 6th January 2021. [source: https://beta.
microreact.org/project/vVnFfZG7o3qYUJ6bnDs3Jo-cog-uk-2020-12-20-sars-cov-2-in-the-uk].
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3.2 Cellular entry of SARS-CoV-2
The SARS-CoV-2 virus enters human cells via interaction of the spike protein with 
the Angiotensin Converting Enzyme 2 protein (ACE2) [8]. ACE2 is integral to the 
renin-angiotensin-aldosterone (RAAS) system. Originally thought to have a systemic 
effect on maintenance of blood pressure and electrolyte balance, it has been found to 
be involved in inflammatory responses in many tissues including the cardiovascular 
system [9]. Activation of the RASS system has been associated with the development 
of hypertension, myocardial infarction, chronic heart failure, diabetes and inflam-
matory processes in lung tissue [10]. SARS-CoV-2 and ACE2 protein interaction is 
like the SARS-CoV virus responsible for the original SARS outbreak [11].
ACE2 is a metallopeptidase and is found in virtually all cell types. It is highly 
expressed on cell surfaces in lung alveolar epithelium, intestinal enterocytes as well 
Figure 3. 
Phylogenic tree of alpha and beta coronaviruses. MERS, Middle East respiratory syndrome; SARS, severe acute 
respiratory syndrome; SARS-COV-2, severe acute respiratory syndrome coronavirus 2.
Figure 4. 
(a) Schematic structure of a coronavirus particle [source: Peiris et al., [6]] (b) transmission electron 
microscopy image of an isolate from the first case of COVID-19 in the USA. The spherical extracellular viral 
particles contain cross-sections through the viral genome seen as black dots [source: cdc.gov].
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as on vascular endothelial cells [12]. This is especially important in those individuals 
with underlying cardiovascular diseases as expression of ACE2 in the vasculature 
is altered [13]. This will be detailed further in the chapter under cardiovascular 
involvement. Following internalisation via vesicle entry, the ACE2 surface proteins 
are downregulated, potentiating the increasing physiological effects of angiotensin 
II (Figure 5) via proinflammatory mediators [14].
3.3 Routes of transmission of SARS-CoV-2
The major route of transmission in the human population is from person-to-per-
son via respiratory droplets when infected individuals cough, sneeze and talk when 
in close contact with another person [15]. Susceptible individuals inhale droplets 
shed from an infected individual near one another. The risk of infection depends on 
the size of the particles and droplets, the extent of viral shedding from the infected 
individual, the force of expulsion of droplets from an infected individual, the 
proximity between infected and uninfected individuals as well as environmental 
factors such as air density, humidity and wind speed [16]. Aerosol transmission 
is an alternative route of infectivity; however, this has been subject to significant 
debate and scientific study.
Aerosol transmission occurs when proteins and pathogens float in the form of 
aerosols after droplets dry out. This may be possible with SARS-CoV-2 in enclosed 
areas if individuals are exposed to high levels of infected aerosol material such as in 
care home settings and hospital wards; thus, pose a risk to healthcare workers and 
others in close contact with infected individuals over a long period of time. Aerosol 
transmission is often successful with particles with a diameter of 5–10 μm and 
can be carried over a large distance, whereas droplets are often larger than 10 μm 
and fall from the air within 1 metre hence the global adoption of spacing between 
individuals of 1–2 metres [17].
Oral-faecal transmission is another potential route of person-to-person 
transmission [18]. SARS-CoV-2 has been detected in faecal material from known 
COVID-19 patients [15, 19]. This is unsurprising given the clinical gastrointestinal 
manifestations in some individuals. This poses as a rapid transmission route in 
Figure 5. 
Viral entry of SARS-CoV-2 in host cells via the ACE2 surface protein. Following entry ACE2 is downregulated 
resulting in upregulation of angiotensin II (Ang II) which via its AT1R receptor induces NF-kB signalling 
pathways to increase expression of inflammatory cytokines such as interleukins (IL-1, IL1β, IL-6), 
matrixmtalloproteinases (MMP-1, MMP-3) and tumour necrosis factor alpha (TNF-α). [source: Banu 
et al. [14]].
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persons unable to maintain good hygiene such as neonates/infants, the infirm and 
the elderly with cognitive decline such as dementia. It is also a source of environ-
mental viral transmission in developing countries with poor sanitation and no 
running clean water and soap for adequate hand washing. This has wider impact 
on those healthcare systems who provide screening of faecal material for colorectal 
cancer screening [20].
SARS-CoV-2 has not been detected in semen from individuals who have 
either recovered from or have active COVID-19 infections [21, 22], suggesting 
sexual transmission is very unlikely. Maternal-fetal transmission however has 
been described in a small number of clinical cases. A neonate born in Wuhan to a 
COVID-19 positive woman tested positive for COVID-19 in a nasopharyngeal swab 
taken 2 days after birth, however this does not confirm maternal-fetal transmission. 
Oher studies refute vertical intrauterine transmission from mother to child [23, 24] 
however a recent meta-analysis suggests vertical transmission is possible normally 
in the third trimester but the incidence is low at 2–3% [25]. This is in part due to the 
ACE2 receptor portal of SARS-CoV-2 entry into cells being expressed in low con-
centrations at the maternal-fetal barrier, limiting the route of vertical transmission.
4. General clinical presentation of COVID-19
With the emergence of the pandemic in earnest at the beginning of 2020, the 
medical and scientific literature has been flooded with case reports and small 
clinical series often on a regional (district/country) basis. In general, the clinical 
presentation of patients with SARS-CoV-2 is very similar to that of other coronavi-
rus infections in humans. For the majority of those infected, individuals are either 
asymptomatic or have a mild fever, novel dry cough or anosmia (loss of smell). 
Figure 6. 
Respiratory and systemic signs and symptoms associated with COVID-19 [source: Rothan and Byareddy [26]].
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In the small minority of those who are severely affected, the overriding clinical 
presentation is of respiratory distress however other symptoms are case-dependent.
The reported clinical characteristics and prognosis of COVID-19 patients varies 
greatly (Figure 6). A recent comprehensive meta-analysis has been performed of 
clinical characteristics, risk factors and outcomes by Li and colleagues [27]. This 
vast analysis includes 212 studies from 11 countries involving 281,461 laboratory 
confirmed COVID-19 cases. The mean age of patients was 46.7y (95%CI 42.8y 
to 50.6y) with 51.9 (95%CI 50.4 to 53.2) males. The mean time of illness onset to 
hospital admission was 5.5 days (95%CI 4.6 to 6.4 days) with an incubation period 
of 5.3 days (95%CI 4.5 to 5.9 days). Clinical presentation characteristics and out-
come are summarised in Table 1. 79% of subjects were febrile and 53% developed 
a cough. Renal and hepatic injury occurred in 4% and 7% respectively but cardiac 
injury was higher at 9%. Overall mortality was reported to be 6% but this differed 
greatly by country. Mortality was significantly associated with age, male sex, the 
presence of hypertension or diabetes mellitus [27].
5. Chest imaging
Thoracic imaging is an important diagnostic tool in screening, early diagnosis 
and monitoring of patients with COVID-19. Although computed tomography 
(CT) is the gold standard, chest x-ray (CXR) is a cheap, readily available and a 
Participants (n) Value (%) 95% CI
Clinical Presentation
Fever 15,921 78.8 76.2 to 81.3
Fatigue 13,680 32.2 28.0 to 36.6
Myalgia 10,728 21.3 18.1 to 24.9
Malaise 2,526 37.9 29.5 to 47.1
Respiratory symptoms
Cough 12,782 53.9 50.0 to 57.7
Expectoration 6,072 7.5 5.7 to 9.6
Chest pain 3,512 9.0 6.2 to 13.1
Shortness of breath 11,205 18.9 15.7 to 22.8
Gastrointestinal symptoms
Nausea 5,599 6.9 5.3 to 9.1
Vomiting 7,484 4.7 3.8 to 5.8
Diarrhoea 12,142 9.5 7.8 to 11.5
Prognosis
Renal injury 77,679 3.6 1.2 to 10.1
Hepatic injury 77,331 7.9 2.6 to 21.7
Cardiac Injury 1,417 9.4 4.5 to 18.8
Mechanical ventilation 6,152 7.1 4.5 to 11.0
Mortality 52,808 5.6 4.2 to 7.5
Table 1. 
Clinical characteristics and outcomes in COVID-19. Analysis of 281,461 confirmed cases. 95% CI, confidence 
interval. [source, data from Li et al. [27]].
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faster alternative. CXR lacks sensitivity for diagnosis in the early presentation of 
COVID-19 being 55% within two days, increasing to 79% at 11 days from onset of 
symptoms. Specificity decreased over time from 83–70% at ≤2d and > 11d respec-
tively [28]. In approximately 60% of cases, CXR reveals interstitial and airspace 
opacities in an IA pattern. This increased over time from 51% at ≤2d vs. 73% at 
>11d [28]. Normal and mild severity CXR findings were the largest factor behind 
false-negative CXR and often associated with young age and some ethnic groups. In 
a real-world reader performance study by Cozzi and colleagues [29], experienced 
radiologist (>10 y experience) reported CXR with higher specificity than less expe-
rienced (<10 y experience) radiologists. Comparative CXR images from different 
respiratory diseases and a normal CXR are shown in Figure 7.
Computed tomography (CT) is the preferred radiological procedure for diagno-
sis. A Cochrane review of CT for diagnosis of COVID-19 found that in 84 studies 
with 8,279 participants; the pooled sensitivity for diagnosis was 86% (95%CI 
90–95%) with a very low specificity of 18% (95%CI 4–56%) [31]. A retrospective 
study of chest CT findings in 121 symptomatic patients in 4 centres in China has 
been reported [32]. The classical findings were bilateral and peripheral ground-glass 
Figure 7. 
Comparative chest X-ray findings in (a) normal CXR (b) SARS (c) MERS (d) COVID-19. [source: Images 
adapted from Pereira et al. [30]].
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consolidative opacity. 56% of subjects had normal CT images in the early phase (0 to 
2 days) of the disease but more frequent in longer infections with consolidation, 
bilateral and peripheral and greater total lung involvement. Bilateral involvement 
occurred in 28%, 76% and 88% of early (0–2 days), intermediate (3–5 days) and late 
(6–12 days) infection times respectively. Further notable CT findings include linear 
opacity, crazy-paving patterns and reverse halo sign (Figure 8).
Following isolation and treatment, most COVID-19 patients stabilise and 
become well. Further CT imaging demonstrates regression of infection with 
absorbed lesions, and some cord-like shadows.
6. Gastrointestinal symptoms in COVID-19
Gastrointestinal (GI) symptoms are emerging in patients with COVID-19. This is 
due to the presence of the ACE2 receptor expressed in the GI tract [33, 34].
COVID-19 patients present with GI symptoms such as diarrhoea (10% of 
patients) with nausea and vomiting less common [35]. In a meta-analysis of 35 
studies, 29 studies reported gastrointestinal symptoms in 6,064 COVID-19 patients 
with a pooled prevalence of gastrointestinal comorbidities of 4%. (95% CI 2 to 5%; 
range 0 to 15%; I2 = 74%). The pooled prevalence of digestive symptoms was 15% 
(10 to 21%; range: 2 to 57%; I2 = 96%) with nausea or vomiting, diarrhoea, and loss 
of appetite being the three most common [36].
Figure 8. 
Representative characteristic findings of COVID-19 infection on thoracic CT imaging: (a) axial CT image 
obtained without intravenous contrast. 36y male showing bilateral ground-glass opacities in upper lobes 
with rounded morphologies (arrows); (b) axial CT image. 65 y female, showing bilateral ground-glass and 
consolidative opacities with striking peripheral distribution (arrows); (c) axial CT image obtained without 
intravenous contrast material in a 43 y female, demonstrating crazy-paving pattern manifested by right lower 
lobe ground-glass opacification with interlobular septal thickening (arrows) with intralobular lines. (d) 
Axial CT image obtained in a 22y female, showing an area of faint ground-glass opacification in left upper 
lobe with a ring of denser consolidation or reverse halo sign (arrow). [source: Images modified from Bernheim 
et al. [32]].
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7. Cardiovascular findings in COVID-19
In addition to respiratory and gastrointestinal symptoms, cardiovascular 
involvement is also common amongst patients with COVID-19. The symptoms are 
wide-ranging in manifestation and severity and are more common in the elderly 
and those hospitalised with the infection. Previous influenza epidemics have been 
associated with an increased prevalence of myocardial infarction, myocarditis 
and chronic/congestive heart failure [37]. Both SARS and MERS were associated 
with either bradycardia, tachycardia, cardiomegaly, diastolic impairments, cardiac 
arrest, cardiomegaly and acute cardiac failure [38–40].
Patients with cardiovascular risk factors or established cardiovascular disease 
disproportionately suffer with severe forms of the infection with worse clinical 
prognosis and outcome. In one of the earliest reports of clinical characteristics of 
COVID-19 from Wuhan China; 14% of 138 patients demonstrated baseline cardio-
vascular disease and 31% had hypertension [41]. Similar data has been reported 
in other population studies from Wuhan, China [42–44]; Italy [45, 46]; Iran [47], 
United Kingdom [48] and the USA [49] to varying cardiac involvement.
The pathophysiological mechanism of cardiac injury in COVID-19 infection are 
similar to those associated with other influenza pandemics and human coronavirus 
diseases (SARS and MERS). Although the pathophysiological mechanisms injury is 
not fully established in COVID-19 patients, it is likely that the elevation is related to 
(1) Systemic inflammatory involvement, cytokine storm mediated through T-cell and 
monocytes resulting in myocarditis. Often patients have concomitant elevations in 
C-reactive protein (CRP), eosinophil sedimentation rate (ESR) (2) Hypercoagulability. 
Figure 9. 
Pathophysiological mechanisms of acute myocardial injury in COVID-19 infection.
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Haematological differentials along with abnormal clotting factors and elevated 
D-dimer result in haemostasis and thrombosis as evident of coronary microvascular 
disease. (3) Endothelial injury causing diffuse disruption to the vasculature in several 
organs including the heart. (4) Down regulation of ACE2 expression in cardiomyocytes 
and loss of the protective signalling pathway (5) Inflammatory and stress response 
causing plaque rupture in those subjects with active coronary artery disease (Figure 9).
8. Biomarker evidence of myocardial injury in COVID-19
A significant proportion of patients requiring hospitalisation, intensive therapy 
and the need for mechanical ventilation demonstrate elevation of biomarkers of 
cardiac injury [42–44, 50–55], namely cardiac troponin T (cTnT); cardiac troponin 
I (cTnI) and the natriuretic peptides N-terminal pro-B-type natriuretic peptide 
(NTproBNP) and the active hormone b-type natriuretic peptide (BNP).
The evidence of cardiac injury in COVID-19 is wide ranging and its associa-
tion with mortality differs between studies. Li and collages performed a meta-
analysis of 28 studies involving 4,189 individuals with COVID-19. Elevated 
cardiac biomarkers (cTn, creatine kinase-MB, myoglobin and NTproBNP were 
associated with the severe forms of infection compared to subjects with mild 
forms of the disease (Figure 10). In addition, those with evidence of COVID-19 
Figure 10. 
Forest plot of cardiac biomarker standard mean difference between severe and less severe cases [source, 
Li et al. [53]].
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related cardiac injury was more likely to die than those without (summary risk 
ratio 3.85 (95%CI 2.13 to 6.96, p = <0.001) [53].
With the emergence of cTn elevation in severe COVID-19 disease, attention 
turned to its prognostic value. A study of 416 COVID-19 patients by Shi and col-
leagues found elevated cTnI in 1 in 5 presenting patients, and positive cTn patients 
were more likely to require non-invasive ventilation and develop acute respiratory 
distress syndrome or acute kidney injury. In addition, the mortality rate was 10-fold 
higher in those patients with evidence of myocardial injury [43]. This is consistent 
with other studies.
Guo and colleagues reported 28% myocardial injury demonstrated by an 
elevated cTnT in 187 COVID-19 patients; with an in-hospital mortality of 60% and 
a higher incidence of mortality (69%) in those cTnT positive patients with underly-
ing cardiovascular disease compared to 38% mortality in those without a cardiac 
history [55].
Figure 11. 
Kaplan–Meier survival analysis of survival by (a) dichotomised cTnI over 40 days and by (b) cTnT quartiles 
over 30 days. [sources: Adapted from Cinar, et al. [61] and Almeida Jr. et al. [62] respectively].
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Giustino and colleagues investigated 305 COVID-19 patients in 7 hospitals in 
New York City, USA and Milan, Italy. Patients exhibiting myocardial injury has 
elevated inflammatory markers, electrocardiographic abnormalities as well as 
transthoracic echocardiographic (TTE) evidence of left ventricular wall motion 
abnormalities, global left ventricular dysfunction, grade II or III left ventricular 
diastolic dysfunction, right ventricular dysfunction and pericardial effusion. 
In-hospital mortality was 32% in patients with myocardial damage and TT abnor-
malities, 19% with cTn positive myocardial injury only and 5% in those without 
evidence of cardiac involvement [56].
Lala and colleagues investigated the degree of myocardial injury in laboratory-
confirmed cases of COVID-19 and correlated findings with outcome [57]. 36% of 
2,736 patients had an elevated cTnI (>0.03 ng/mL).
Seven studies have investigated the prognostic value of elevated cTn in COVID-
19. Five utilised cTnI [57–61], one cTnT [62] and one with combined cTnT and cTnI 
from different institutions [63]. In all cases, an elevated cTn (cTnI, Figure 11a; 
cTnT Figure 11b) was associated with poor outcome; be it in-hospital mortality, 
or combined endpoints of all-cause mortality and need for mechanical ventila-
tion. Lala and colleagues [57] identified even minor elevations in cTnI (0.03 to 
0.09 ng/ml) were associated with mortality (Hazard ratio 1.75; 95%CI = 1.37 to 
2.24, p < 0.001). Those with greater cTnI concentrations above 0.09 ng/L conferred 
greater risk (Hazard ratio 3.03, 95% CI 2.42 to 3.80).
The underlying pathological mechanisms resulting in elevation in cTn in 
patients with COVID-19 have not been fully elucidated. The vast majority of 
reported cardiovascular complications in COVID-19 refer to acute cardiac injury, 
with an incidence of 8–22%. Other mechanisms (% incidence) include pulmonary 
thrombosis and arterial/venous thromboembolism (16–49%); chronic heart failure 
(52% in non-survivors, 12% in survivors); Acute coronary syndromes (44% with 
ST segment elevation myocardial infarction [STEMI]); arrhythmia (17% overall; 
44% vs. 9% in severe and mild cases respectively). A few case reports have demon-
strated myocarditis and pericardial disease [64].
9. Electrocardiographic and echocardiographic changes in COVID-19
The cardiac involvement in COVID-19 is diverse and as such varying different 
findings have been observed with diagnostic tools such as the electrocardiogram 
(ECG) and echocardiography. ECG changes in COVID-19 represent both left and 
right-sided heart disease [65] and are associated with a higher risk of mortality. In a 
study of 756 patients, 90 (12%) of which died (Table 2); one or more atrial prema-
ture contractions right bundle or intraventricular block, ischemic T-wave inversion 
and nonspecific repolarisation were associated with death [65]. These finding were 
ECG Abnormality Odds Ratio 95% CI
One or more atrial premature contraction 2.57 1.23 to 5.36
Right bundle branch or intraventricular block 2.61 1.32 to 5.18
Ischemic T-wave inversion 3.49 1.56 to 7.80
Nonspecific repolarisation 2.31 1.27 to 4.21
Table 2. 
Odds ratio for ECG findings significantly associated with mortality. 95%CI, 95% confidence interval [source: 
McCullough et al. [65]].
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further supported by De Vita and colleagues [66] who observed the ECG on admis-
sion was a helpful tool to identify COVID-19 patients with increased risk of death.
In a retrospective analysis of 319 severe and critically severe COVID-19 cases, 
Wang and colleagues observed 118 (37%) with normal ECG and 201 (63%) abnor-
mal ECG traces. Differences were observed in ST-T changes, sinus tachycardia, 
atrial fibrillation, and atrial tachycardia between the group severity. Sinus tachycar-
dia and atrial fibrillation were the independent risk factors of in-hospital death and 
ventilator use and could be used as an independent predictor of poor outcome [67].
A caveat to ECG induced changes is due to drug therapies given in severe 
COVID-19 infections. Drug-induced changes associated with chloroquine, hydroxy-
chloroquine and azithromycin can result in a prolonged corrected QT (QTc), 
however such elongations do not induce arrhythmia-related death [68].
Echocardiographic findings demonstrate Left and right ventricular abnormali-
ties in 39% and 33% of COVID-19 patients respectively [69]. severe ventricular 
dysfunction or tamponade is observed in approximately 15% of patients. In those 
without pre-existing cardiac disease the echocardiogram is abnormal in roughly 
half of COVID-19 patients with approximately 15% demonstrating severe disease. 
In a study of 90 hospitalised patients with severe (44, 49%) and non-severe (46, 
51%) COVID-19; right ventricular (RV) and left ventricular (LV) functions were 
compared [70]. The RV and LV diameters were larger in severe patients com-
pared to non-severe. Left ventricular ejection fraction (LVEF) were significantly 
(p = <0.001) lower (54.0% ±9.8%) in the severe-infections compared to the non-
severe (61.9 ± 4.8%). Furthermore, pericardial effusions were observed in 23% of 
the severe patients with no observed cases in the non-severe patients.
In a study of 749 known COVID-19 positive patients undergoing transthoracic 
echocardiography (TTE), 38% were found to have LVEF ≤50% and 14% had 
moderately reduced right ventricular function. Stress-induced cardiomyopathy as 
evident by wall motion abnormalities were observed in four patients. A significant 
inverse relationship between cTnT and LVEF was observed (P = −0.34, P = 0.006). 
On the basis of the clinical TTE findings, therapeutic management was altered in 
24% due to concern for a major cardiac even and in 14% where haemodynamic 
instability warranted TTE [71].
Both ECG and echocardiography are useful tools in the identification of left and 
right-sided cardiac dysfunction in COVID-19. Abnormalities are more frequent as 
infection severity increases and are often associated with poor prognosis.
10. Gross cardiac pathology and histopathology
A number of post-mortem (autopsy) studies have been performed on COVID-
19 patients [72–79]. Four main pathological processes are generally observed: (a) 
Diffuse alveolar infiltration and damage with hyaline membrane formation, (b) 
thromboembolic disease in pulmonary and cardiac tissue and peripheral deep 
vein thrombosis, (c) hemophagocytes and (d) depletion of immune related cells 
[80, 81]. Gross cardiac examination (Figure 12) often reveals enlarged hearts 
[75, 76, 79] and the myocardium appears pale and flabby [76]. Thrombotic pathol-
ogy is predominantly found in the lung, being present in 90% of cases; in 60% of 
hearts and 45% of kidneys [80].
In nine community deaths with suspected COVID-19 infections, Youd and 
colleagues did not observe any cases of myocarditis, however one case of bacterial 
bronchopneumonia had associated myocarditis. Contraction band necrosis was 
observed in a 86y Caucasian Male who had an underlying history of hypertension 
and cardiovascular disease. Cardiac amyloidosis was evident in one case [79].
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An Italian study of 22 autopsies (18 with comorbid conditions, 4 without) dem-
onstrated significant pulmonary and cardiovascular pathologies. All 22 deaths were 
reported as cardiorespiratory failure [76]. Cardiovascular pathologies are reported 
in Table 3.
A systematic review of histopathological findings by physiological system have 
identified cardiovascular findings such as focal lymphocytic inflammation, acute 
cardiomyocyte necrosis, presence of inflammatory cells and apoptotic bodies [74].
A multicentre study of 21 autopsy examinations by Basso and colleagues [73] 
examined cardiac tissue. Lymphocytic myocarditis was present in 3 (14%) cases, 
two of which were CD4 predominant T-cells, and one CD8 prominent. 86% of cases 
demonstrated interstitial macrophage infiltration. Mild pericarditis was evident 
in 4 cases. Common histological findings from cardiac tissue are presented in 
Figure 13.
Although the underlying mechanisms of cardiac involvement in COVID-19 
infection remain to be fully elucidated, cardiac fibrosis occurs in tandem with 
local and systemic inflammatory responses [84]. Whilst these mechanisms are 
designed to facilitate healing following tissue damage, an excess of the inflamma-
tory response along with the development of fibrotic tissue are pathological drivers 
for global organ damage. Overt inflammation and fibrosis in the heart can result in 
abnormal cardiac remodelling potentiating the development of acute and chronic 
heart failure. Anti-inflammatory and anti-fibrotic therapies are in general unsuc-
cessful in improving damaged cardiac tissue function. With respect to COVID-19, 
Figure 12. 
Gross macroscopic cardiac pathology in COVID-19. (a) Fibrinous myocarditis; (b) cardiac hypertrophy with 
pale flabby myocardium; (c) macroscopic right coronary artery thrombosis (green arrow); (d) contained 
aortic dissection (green arrow) and fibrinous pericarditis (red arrow and H&E histology inset) in a 22y male; 
(e) gross marantic endocarditis with associated H&E histology inset; (f) extreme right ventricular dilatation 
with intraventricular septum straightening in a formalin fixed heart; (g) transverse sections demonstrating 
extensive right ventricular dilation of (i) 2.9:1.7 cm, (ii) 4.0:0.9 cm, (iii) 3.6:3.4 cm. [sources: Adapted from 
Youd et al. [79], Hanley et al. [80], Fox et al. [82, 83]].
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further work is required to identify potential therapeutic targets of regulation and 
moderation of cardiac fibroblast function and thus reduce the burden of inflamma-
tory-responsive fibrotic-based heart failure.
11. Conclusion
The novel Coronavirus disease, COVID-19 that emerged just over one year 
ago has caused substantial disruption to everyday life for every human on the 
Histopathological findings COVID-19 deaths with comorbid 
conditions (n = 18) (%)
COVID-19 deaths without 
comorbid conditions (n = 4) (%)
Myocarditis 9 (50.0) 3 (75.0)
Vasculitis 5 (27.8 3 (75.0)
Inflammatory infiltrate 13 (72.3) 3 (75.0)
Focal necrosis 6 (33.4) 2 (50.0)
Pericarditis 9 (50.0) 4 (100)
Vascular fibrosis 4 (22.3) 2 (50.0)
Table 3. 
Cardiovascular histopathological findings in COVID-19 cadavers with and without comorbid conditions 
[source: Falasca et al. [76]].
Figure 13. 
(a and b) Myocarditis. Biventricular multifocal and diffuse lymphocytic myocarditis (arrows) with 
extensive myocyte injury and previously undiagnosed cardiac amyloidosis (H&E) x50 in an 86y male; (c 
and d) Biventricular multifocal lymphocytic myocarditis (arrows) with myocyte injury (H&E x100). Atrial 
fibrillation developed 2 d before death, 64y male; (e) Increased interstitial macrophage H&E x400) in a 60y 
male; (f) Increased macrophage cells within the myocardial interstitum (H&E x100) in a 73y female; (g) 
Focal lymphocytic pericarditis (arrows, H&E, x400) comprised of (h) CD8+ lymphocytes associated with focal 
myocardial inflammation in the absence of myocyte injury (arrowhead, CD8 immunostaining x400); (I and j) 
Small vessel changes. Microthrombus in a small myocardial artery (a, arrow H&E x100) and organised venous 
thrombosis (b, arrow H&E x100) in a 70y male; (k) Thrombus in a small myocardial vein (arrow, H&E 
x200) in a 71y male; (l) Leucocyte aggregates of eosinophils and mononuclear cells in capillaries and small 
veins (arrow, H&E x400) in a 64y male.[Source: Adapted from Basso et al., [73]].
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planet. In the ensuing year, science and medicine have fought a race against time 
to understand the aetiology and pathogenicity of the disease. The overriding signs 
and symptoms supported by diagnostic testing indicates diffuse alveolar infiltra-
tion with vascular thromboembolic involvement in pulmonary, cardiac and renal 
tissue. Cardiac electrocardiography, echocardiography and cardiac biomarker 
testing are vital in the identification and management of patients with COVID-19 
and concomitant cardiovascular involvement. Pathological findings at autopsy aid 
in the understanding of the pathophysiology of cardiovascular involvement in the 
disease. With the development of vaccines and mass vaccination programmes for 
the vulnerable along with herd immunity in the young, the global population will 
survive this novel pandemic but to significant cost both socially, economically and 
emotionally.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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